Japan's Takeda says Q3 profit slid 38%, trailing analyst estimates
Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates, as ...
Takeda Pharmaceutical (TAK) Projected to Post Quarterly Earnings on Thursday
Takeda Pharmaceutical (NYSE:TAK – Get Free Report) is projected to announce its earnings results before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of ...
Takeda Pharmaceutical Expected to Post Lower Third-Quarter Net Profit -- Earnings Preview
NET PROFIT FORECAST: Takeda is expected to post a 59% drop in net profit to 43.58 billion yen, equivalent to $280.2 million, for the three months ended Dec. 31, according to a poll of analysts by data ...
Japan's Takeda raises full-year forecast after Q3 profit trails forecast
Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...
FiercePharma5d
Takeda bids adieu to Uloric after gout med's gradual fade from glory
The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. | Following some ...
FierceBiotech2d
Takeda regains home rights to phase 3-stage depression drug from Neurocrine
Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset ...
Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and ...
Takeda Canada Announces Héma-Québec's Addition Of HyQvia To Plasma Product List
Takeda Canada Inc., the Canadian organization of Takeda Pharmaceutical Co. Ltd. (TAK) announced Wednesday that non-profit ...
AFP1h
Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth
Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advancement of its Growth & Launch ...